Customize your JAMA Network experience by selecting one or more topics from the list below.
Burcu M, Zito JM, Metcalfe L, Underwood H, Safer DJ. Trends in Stimulant Medication Use in Commercially Insured Youths and Adults, 2010-2014. JAMA Psychiatry. 2016;73(9):992–993. doi:10.1001/jamapsychiatry.2016.1182
Stimulants are the most commonly prescribed treatment of attention-deficit/hyperactivity disorder (ADHD) in youths, and according to a nationally representative US household survey, there has been a sizeable increase in stimulant use among youth, from 4.0% between 1996 and 1998 to 6.6% between 2010 and 2012.1 Also, during the last decade, the US Food and Drug Administration approved an indication for stimulant use in adults to treat ADHD.
Studies of office-based physician visits by adults showed that the proportion of visits with a prescribed stimulant grew 7-fold, from 0.1% between 1994 and 1997 to 0.7% between 2006 and 2009,2 and the percentage of visits with ADHD diagnosis doubled from 0.3% between 1999 and 2002 to 0.7% between 2007 and 2010.3 Also, compared with youth ADHD visits, adult ADHD visits comprised a distinctly larger proportion of female and commercially insured visits.3 However, little is known about the trends in stimulant use within the past few years, specifically within commercially insured US populations. This study uses data from a large, commercially insured population to characterize recent trends and patterns of stimulant use according to age and sex.
Create a personal account or sign in to: